Literature DB >> 3146771

Scopolamine produces environment-specific conditioned activity that is not blocked by pimozide in rats.

E J Mazurski1, R J Beninger.   

Abstract

A classical conditioning paradigm was employed to determine if the stimulant effects of the anticholinergic scopolamine could show conditioning. In experiment 1 rats had 12 60-min pairings of scopolamine (1.0 or 8.0 mg/kg, IP) with a distinctive environment that monitored horizontal and vertical activity. Experimental (paired) groups received the drug 30 min prior to each session, whereas control (unpaired) groups received saline. Following each session the Paired groups were injected with saline, and the Unpaired groups received the same doses of scopolamine. After every fourth pairing a test session assessed conditioning by comparing activity of paired und unpaired groups in response to saline. Scopolamine enhanced horizontal activity, although conditioning was seen only with 8.0 mg/kg. The low dose increased vertical activity, whereas an initial decrease was observed with 8.0 mg/kg. However, conditioned vertical activity was seen with both doses. Experiment 2 assessed the possible role of dopamine in conditioning with 8.0 mg/kg scopolamine. Rats treated as in experiment 1 were additionally given 0.4 mg/kg pimozide 4 h prior to each pairing session. Pimozide did not block scopolamine's stimulant effect. Conditioned horizontal and vertical activity were also observed, suggesting that this effect may be mediated by direct changes within cholinergic systems.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3146771     DOI: 10.1007/bf00216065

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  22 in total

1.  Evidence from rats that morphine tolerance is a learned response.

Authors:  S Siegel
Journal:  J Comp Physiol Psychol       Date:  1975-07

2.  Apomorphine: chemistry, pharmacology, biochemistry.

Authors:  F C Colpaert; W F Van Bever; J E Leysen
Journal:  Int Rev Neurobiol       Date:  1976       Impact factor: 3.230

3.  The role of locomotion in conditioning methylphenidate-induced locomotor activity.

Authors:  H L Schreiber; G W Wood; R H Carlson
Journal:  Pharmacol Biochem Behav       Date:  1976-04       Impact factor: 3.533

4.  Cholinergic-anticholinergic antagonism in parkinsonism.

Authors:  R C Duvoisin
Journal:  Arch Neurol       Date:  1967-08

5.  Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action.

Authors:  J T Coyle; S H Snyder
Journal:  Science       Date:  1969-11-14       Impact factor: 47.728

6.  Drug-environment interaction: context dependency of cocaine-induced behavioral sensitization.

Authors:  R M Post; A Lockfeld; K M Squillace; N R Contel
Journal:  Life Sci       Date:  1981-02-16       Impact factor: 5.037

7.  Classical conditioning, decay and extinction of cocaine-induced hyperactivity and stereotypy.

Authors:  G A Barr; N S Sharpless; S Cooper; S R Schiff; W Paredes; W H Bridger
Journal:  Life Sci       Date:  1983-10-03       Impact factor: 5.037

8.  Automating the measurement of locomotor activity.

Authors:  R J Beninger; T A Cooper; E J Mazurski
Journal:  Neurobehav Toxicol Teratol       Date:  1985 Jan-Feb

9.  Comparison of the ability of (+)-amphetamine and caffeine to produce environment-specific conditioning.

Authors:  R S Herz; R J Beninger
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

10.  Age-dependent effects of scopolamine on avoidance, locomotor activity, and rearing.

Authors:  R H Bauer
Journal:  Behav Brain Res       Date:  1982-07       Impact factor: 3.332

View more
  1 in total

1.  Retarded acquisition and reduced expression of conditioned locomotor activity in adult rats following repeated early maternal separation: effects of prefeeding, d-amphetamine, dopamine antagonists and clonidine.

Authors:  K Matthews; F S Hall; L S Wilkinson; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.